Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘opdivo’

Lung cancer doctors eye Merck’s Keytruda over Bristol’s Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Bron: Reuters Meer lezen »

Bristol-Myers Squibb’s wonder drug – Opdivo

New data for Bristol-Myers Squibb’s Opdivo to treat head and neck cancer showed superior survival compared with current standard chemotherapies in late stage trials, the company said. The trial was stopped early due to the survival benefit observed with Opdivo, BMS said following recommendations from an independent monitoring committee.

Bron: InPharm.com Meer lezen »

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to treat patients with the most common forms of advanced lung and advanced kidney cancer.

Bron: InPharm.com Meer lezen »

FDA approves Opdivo to treat advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

Bron: U.S. Food and Drug Administration: Press releases Meer lezen »

Bristol-Myers Squibb notches kidney cancer first with Opdivo

Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is a current standard therapy in advanced kidney cancer. All patients in the study, named CheckMate -025, had received prior treatment for their cancer.

Bron: InPharm.com Meer lezen »

Schippers: ‘Vergoeding nivolumab snel regelen’

Zorgverzekeraars en de leverancier van het medicijn nivolumab (Opdivo) voor de behandeling van longkanker moeten zo snel mogelijk afspraken maken over de vergoeding van het medicijn en van de organisatie van de zorg eromheen.

Bron: Medisch Contact nieuws Meer lezen »

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug in its second indication. BMS adds lung cancer to advanced melanoma in the list of conditions for which the drug is available, after its launch as a treatment for locally advanced or metastatic squamous non-small cell […]

Bron: InPharm.com Meer lezen »

BMS halts Opdivo kidney cancer trial early

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after the treatment improved overall survival. The phase III study investigated Opdivo (nivolumab) compared to Novartis’ Afinitor (everolimus) in 821 previously treated patients with advanced or metastatic renal cell carcinoma.

Bron: InPharm.com Meer lezen »

ASCO 2015 roundup: immuno-oncology hits its stride

One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks before the world’s first approved PD-L1 inhibitor immunotherapy, Bristol-Myers Squibb’s Opdivo (nivolumab), was shown its first green light in Japan.  

Bron: InPharm.com Meer lezen »

Bristol─Myers Squibb, Pharmacyclics & Janssen enter clinical trial agreement to evaluate Opdivo and Imbruvica in non─Hodgkin lymphoma

Bristol─Myers Squibb Company, Pharmacyclics, and Janssen Research & Development, have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol─Myers Squibb’s investigational PD─1 immune checkpoint inhibitor, Opdivo (nivolumab).

Bron: Pharma Biz Meer lezen »

|